Insider

Boston Scientific announces the departure of Arthur Butcher and the promotion of Joe Fitzgerald

Boston Scientific said Arthur C. Butcher will leave his role as executive vice president and group president, MedSurg and Asia Pacific, and will become a senior advisor through February 26, 2027 with a base salary of $780,000. Joe Fitzgerald is promoted to executive vice president and chief operating officer with a base salary of $1,050,000, a target bonus of 110% and a planned equity grant of $7 million.

Verified against 4 archived primary sources · SHA-256 recorded Inspect sources & citations ↓
white wooden desk on hallway inside building
Photo by Brandon Holmes on Unsplash
$780,000
Butcher base salary
$1,050,000
Fitzgerald base salary
$7 million
Equity grant

Key points

  • Arthur C. Butcher informed the company on September 21, 2026 that he will leave the position of executive vice president and group president, MedSurg and Asia Pacific, effective January 1, 2027.
  • Butcher as senior advisor will receive a base salary of $780,000, adding to the company’s cash outlay.
  • If Fitzgerald meets performance targets, his bonus could reach 110% of base salary.

What happened

Arthur C. Butcher informed the company on September 21, 2026 that he will leave the position of executive vice president and group president, MedSurg and Asia Pacific, effective January 1, 2027. He will remain a senior advisor through February 26, 2027, receiving a base salary of $780,000 prorated to his retirement date. Under the Retirement Agreement, he will receive payments and benefits similar to those provided under the company’s Executive Retirement Plan, the 2026 Annual Bonus Plan and the Long‑Term Incentive Program.

Joe Fitzgerald, formerly executive vice president and group president, Cardiovascular, is promoted to executive vice president and chief operating officer effective January 1, 2027. In the new role he will oversee global operations, business units and regions. He will supervise Lance Bates (global Interventional Therapies segment), Nick Spadea‑Anello (Rhythm Solutions) and Stephen Morse (MedSurg and Asia Pacific).

Why it matters

Butcher as senior advisor will receive a base salary of $780,000, adding to the company’s cash outlay. Fitzgerald will have a base salary of $1,050,000 per year. His target bonus equals 110% of base salary. The company plans to grant him equity worth $7 million, expected in February 2027.

When it could help

If Fitzgerald meets performance targets, his bonus could reach 110% of base salary. The $7 million equity grant could increase in real value if the stock price rises. He will remain eligible for the annual bonus plan.

Risks and uncertainties

The company reserves the right to change or cancel any compensation or retirement plan, including the annual bonus plan, deferred bonus plan and executive retirement plan. The filing notes that future statements may not match actual results. Boston Scientific retains the right to terminate an employee without cause and notice.

What to watch

Investors should watch the actual base salary and bonus paid to Fitzgerald for 2027. They should also confirm the size and timing of the equity grant. Any board decisions to change the annual or deferred bonus plan should be tracked in future filings.

Original sources

  1. 8-K filing, September 23, 2026September 23, 2026SHA-256 of our archived copy 9153f6891e93…
  2. 8-K filing, October 7, 2026October 7, 2026SHA-256 of our archived copy 1003fb9573b6…
  3. 8-K EX-99.1 filing, October 7, 2026October 7, 2026SHA-256 of our archived copy 875d05bcac58…
  4. 8-K EX-10.1 filing, October 7, 2026October 7, 2026SHA-256 of our archived copy d2ea82ff5cf8…
Cite this article

The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.

Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards